Literature DB >> 8670597

CD8 lymphocyte subsets in active polymyalgia rheumatica: comparison with elderly-onset and adult rheumatoid arthritis and influence of prednisone therapy.

L Boiardi1, C Salvarani, P Macchioni, M Casadei Maldini, R Mancini, E Beltrandi, I Portioli.   

Abstract

The aim of this study was to evaluate CD8 lymphocyte subsets in active polymyalgia rheumatica (PMR), to determine whether low percentages of CD8+ cells could be used to differentiate PMR from elderly-onset (EORA) and adult rheumatoid arthritis (RA), and to investigate the effects of prednisone on CD8 lymphocyte subsets. A significant reduction of percentages and absolute numbers of CD8bright+ cells was observed in patients with active PMR. Both CD8bright+, CD57- and CD8bright+, CD57+ subsets were significantly reduced. Reduced percentages of CD8+ cells were observed in 55% of patients with active PMR/giant cell arteritis (GCA), in 23% with EORA and in 44% with adult RA. Prednisone therapy in PMR patients, after only 1 week, increased the lymphocyte count and the absolute numbers of lymphocyte subsets significantly. However, the percentages of CD8bright+ cells remained persistently low for the 2 yr study period in 80% of the patients with low pre-treatment levels. Our results demonstrate that CD8 cell percentage is a poor epidemiological discriminator for PMR diagnosis. Notwithstanding the rise in absolute numbers of CD8 cell subsets induced by prednisone, the persistently low percentages of CD8+ cells in a group of PMR patients indicate an abnormality connected with the disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8670597     DOI: 10.1093/rheumatology/35.7.642

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  5 in total

Review 1.  Genetic and environmental factors in polymyalgia rheumatica.

Authors:  M A Cimmino
Journal:  Ann Rheum Dis       Date:  1997-10       Impact factor: 19.103

Review 2.  Could Lymphocyte Profiling be Useful to Diagnose Systemic Autoimmune Diseases?

Authors:  Guillermo Carvajal Alegria; Pierre Gazeau; Sophie Hillion; Claire I Daïen; Divi Y K Cornec
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

3.  Monocyte chemoattractant protein 1 (MCP-1) in temporal arteritis and polymyalgia rheumatica.

Authors:  T Ellingsen; P Elling; A Olson; H Elling; U Baandrup; K Matsushima; B Deleuran; K Stengaard-Pedersen
Journal:  Ann Rheum Dis       Date:  2000-10       Impact factor: 19.103

4.  Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study.

Authors:  R Caporali; C Montecucco; O Epis; F Bobbio-Pallavicini; T Maio; M A Cimmino
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 5.  Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.

Authors:  Dario Camellino; Eric L Matteson; Frank Buttgereit; Christian Dejaco
Journal:  Nat Rev Rheumatol       Date:  2020-08-05       Impact factor: 20.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.